Navigation Links
New Research Shows Antidepressants May Thwart Breast Cancer Treatment
Date:5/30/2009

Popular antidepressants taken with tamoxifen can increase the risk of breast cancer recurrence

PHILADELPHIA, May 30 /PRNewswire-USNewswire/ -- A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast cancer recurrence in women taking both medications. The antidepressants inhibit an enzyme, CYP2D6, which helps tamoxifen work effectively.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090530/DC24767LOGO)

The study was conducted by researchers from Medco and the Indiana University School of Medicine and presented Saturday at the American Society of Clinical Oncology (ASCO) meeting in Orlando.

Approximately 500,000 U.S. women take tamoxifen, a medicine that blocks the effects of estrogen in breast tissue. Estrogen can make certain types of breast cancer (hormone-receptor-positive breast cancers) grow. About 30 percent of women taking tamoxifen also are taking an antidepressant to treat depression and/or to ease hot flashes, a common side effect of tamoxifen. "With more than 100,000 women potentially affected, these data represent a significant health finding," asserts Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist at Lankenau Hospital in the Philadelphia area.

Preliminary, limited information from another study conducted by researchers from the Netherlands appears to offer conflicting results. The Dutch study suggests taking tamoxifen with specific antidepressants doesn't affect breast cancer recurrence rates.

"We don't want to dismiss the findings of the Dutch study; however, from what we've learned, there were fewer women in the Dutch study taking antidepressants in combination with tamoxifen, and it appears that they were taken together for a shorter period of time," says Dr. Weiss. "Regardless, there is considerable evidence in the Medco/Indiana University study, as well as in other smaller studies conducted during the past few years, to give physicians and patients reason to question using certain antidepressants (and other types of medications that might block the CYP2D6 enzyme) together with tamoxifen."

Tamoxifen has been used to successfully treat millions of women diagnosed with hormone-receptor-positive breast cancer. It can reduce the risk of cancer recurrence by about 50 percent.

"With the life-saving advantages of tamoxifen, it's imperative that women taking it derive the greatest benefit they can," says Dr. Weiss. "Women make a daily commitment to tamoxifen and deserve to get the maximum benefit this medicine affords."

She pointed out that there are safe and effective alternatives to manage depression and hot flashes that doctors can offer patients taking tamoxifen. Weiss advises women who have taken tamoxifen along with an antidepressant in the past and those who currently are taking these medicines together to talk to their doctors. Anyone with questions also can find information at Breastcancer.org.

"Since tamoxifen is the cornerstone of care for hundreds of thousands of women across the globe, this study will likely raise a lot of questions about whether to continue to use tamoxifen or change treatments, as well as whether women who stopped taking tamoxifen should restart. These new data represent an important insight into maximizing the effectiveness of breast cancer treatment," says Dr. Weiss.

About Breastcancer.org Breastcancer.org, a nonprofit organization, is the #1 online resource for medically reviewed information on breast health and breast cancer - with over 6,000 pages of medically vetted information and reaching 8 million people worldwide each year.


'/>"/>
SOURCE Breastcancer.org
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
2. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
3. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
4. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
5. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
6. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
7. Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala
8. New Research Shows Nutrition 21s Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings
9. Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):